Vaccination against IL-31 for the treatment of atopic dermatitis in dogs

[...]the here-presented breakthrough therapy of vaccination against IL-31 is not only a promising mode to treat AD in dogs but may also facilitate the development of a similar vaccine in humans. Apoquel from Zoetis, the best current standard for the treatment of AD-induced pruritus in dogs, targets...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology Vol. 142; no. 1; pp. 279 - 281.e1
Main Authors: Bachmann, Martin F., Zeltins, Andris, Kalnins, Gints, Balke, Ina, Fischer, Nina, Rostaher, Ana, Tars, Kaspars, Favrot, Claude
Format: Journal Article
Language:English
Published: United States Elsevier Inc 01.07.2018
Elsevier Limited
Subjects:
Antigens
Atopic dermatitis
Dermatitis
Dogs
Immunization
Quality of life
Skin diseases
Vaccination
Viruses
United States > US
Europe
ISSN:0091-6749, 1097-6825, 1097-6825
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]the here-presented breakthrough therapy of vaccination against IL-31 is not only a promising mode to treat AD in dogs but may also facilitate the development of a similar vaccine in humans. Apoquel from Zoetis, the best current standard for the treatment of AD-induced pruritus in dogs, targets Janus kinase 1, a downstream molecule of a number of cytokines including those pivotal for the allergic reaction, including IL-31.3 In animals and humans, IL-4 and IL-13 are known to be critical for the inflammatory process in AD, while IL-31 is pivotal for the itching.1 Furthermore, an mAb against IL-31 has recently been approved for the treatment of AD in dogs.4 Both Apoquel as well as the mAb against IL-31 have to be given relatively frequently (twice daily for Apoquel and monthly for the antibody). [...]vaccination against IL-31, which should induce a more sustained antibody response, may be a valuable addition or alternative to existing therapies. Dogs were immunized with 100 μg CMVTT formulated in alum on day 0. Because the vaccine was well tolerated and caused no itching, the dose was increased to 300 μg on weeks 3 and 6 (see Fig 1, B, for study outline).
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-2
content type line 14
ObjectType-Letter to the Editor-1
ObjectType-Article-2
ObjectType-Correspondence-1
content type line 23
ISSN:0091-6749
1097-6825
1097-6825
DOI:10.1016/j.jaci.2017.12.994